4 active not recruiting, 1 withdrawn. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 4, Withdrawn 1 |
Follow Oligometastatic Prostate Carcinoma: new trials by email Literature Review of Oligometastatic Prostate Carcinoma trials Research Report on Oligometastatic Prostate Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Computed Tomography - Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 110 | 2024-04-22 | 2026-09-25 |
| 177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study Lutetium Lu-177 PNT2002, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy - Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 93 | 2022-09-02 | 2026-05-26 |
| Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study Biospecimen Collection, Bone Scan, Computed Tomography - Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | NRG Oncology | 194 | 2022-04-20 | 2026-08-17 |
| Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study Apalutamide, Degarelix, Leuprolide Acetate - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2020-11-24 | 2021-01-20 | |
| A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer Intensity-Modulated Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment - Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 84 | 2020-01-06 | 2026-10-20 |
Genital Diseases (4) · Genital Diseases, Male (4) · Genital Neoplasms, Male (4) · Male Urogenital Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Prostatic Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4)
Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · Radiation (2) · Radiosurgery (2) · Radiotherapy (2) · Abiraterone Acetate (1) · Glutamate Carboxypeptidase II (1) · Gonadotropin-Releasing Hormone (1) · Leuprolide (1) · Proton Therapy (1) · Protons (1) · Radiotherapy, Intensity-Modulated (1) · X-Rays (1) · acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (1) · apalutamide (1)
Mayo Clinic (2) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · NRG Oncology (1)
United States (5) · Canada (1)
Amar Kishan, MD (1) · Brian J. Davis, M.D. (1) · Bridget F Koontz (1) · Carlos E. Vargas, M.D. (1) · Eleni Efstathiou (1)
U10CA180868 (1)